← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV23행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
ADCPhase 2
5-FU (5-fluorouracil, 5-fluorouracil (5-FU))
Merck Sharp & Dohme LLC·Colorectal Cancer
ORR 72.7%
Overview
Program
5-fluorouracil (5-FU)
Overview
Company
Merck Sharp & Dohme LLC
Overview
Modality
ADC
Overview
Target
Colorectal Cancer
Overview
Indication
Gastroesophageal Junction; Gastroesophageal Adenocarcinoma
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
MoA
Mechanism
inhibits GC cell proliferation and induces apoptosis by regulating cell-cycle checkpoints and inhibiting oncogenic pathway
MoA
Biomarker
biomarker for metabolic state, B-cell/TLS-associated immune features, and vulnerability to DNA damage-based t
PK/PD
Species
Rabbit, ration, inhibited xenograft
PK/PD
Animal (cat.)
In vitro
PK/PD
Experiment
pharmacokinetic
Toxicology
Species
Rabbit, ration, inhibited xenograft
Toxicology
Animal (cat.)
In vitro
Toxicology
Major finding
Green synthesized cobalt doped graphene quantum dots derived from Boswellia serrata for dual ligand targeted bioimaging and delivery of exemestane.. Major objective of hydrothermal method is to achieve the synthesis of Cobalt doped Graphene quantum dots (Co-GQDs) using natural precursor (Boswellia serrata gum resin). The Co-GQDs were surface engineered with folic acid (FA) and hyaluronic acid (HA)…
Clinical
Primary efficacy
ORR 72.7%
Clinical
ORR
72.7%
Clinical
PFS
10.41
Clinical
OS
19.7
Clinical
Result source
ClinicalTrials.gov NCT04363801
Clinical
Data Tier / Score
A · 68
Clinical
Program phase
PHASE_2
Clinical
Clinical sync
2026년 7월 18일 (8일 전)
5-fluorouracil (5-FU) 비교 | 바이오정보모아